{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:01:06Z","timestamp":1784937666438,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,24]],"date-time":"2027-04-24T00:00:00Z","timestamp":1808524800000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJSP2138"],"award-info":[{"award-number":["JPMJSP2138"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.rmed.2026.108852","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:57:19Z","timestamp":1776783439000},"page":"108852","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy"],"prefix":"10.1016","volume":"257","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9155-3956","authenticated-orcid":false,"given":"Hirotomo","family":"Machiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4930-6997","authenticated-orcid":false,"given":"Kinnosuke","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiroyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7188-674X","authenticated-orcid":false,"given":"Akito","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohide","family":"Komuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tsukaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhei","family":"Kinehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3343-1235","authenticated-orcid":false,"given":"Koki","family":"Moritomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Shoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Mihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keijiro","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Niki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Azuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kumanogoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2026.108852_bib1","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib3","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study","volume":"41","author":"Novello","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib4","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.jtho.2018.08.2035","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.jtho.2020.04.002","article-title":"Assessment of immune-related interstitial lung disease in patients with NSCLC treated with immune checkpoint inhibitors: a multicenter prospective study","volume":"15","author":"Suzuki","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib6","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.rmed.2026.108852_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2026.108852_bib8","article-title":"A real-world study on the effectiveness and safety of pembrolizumab plus chemotherapy for nonsquamous NSCLC","volume":"3","author":"Fujimoto","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.rmed.2026.108852_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.rmed.2026.108852_bib10","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S2213-2600(20)30168-5","article-title":"Interstitial lung abnormalities detected incidentally on CT: a position paper from the Fleischner society","volume":"8","author":"Hatabu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2026.108852_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1164\/rccm.202505-1054ST","article-title":"Approach to the evaluation and management of interstitial lung abnormalities: an official American thoracic society clinical statement","volume":"211","author":"Podolanczuk","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2026.108852_bib12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201809-1652OC","article-title":"Imaging patterns are associated with interstitial lung abnormality progression and mortality","volume":"200","author":"Putman","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108852_bib13","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir. Investig."},{"key":"10.1016\/j.rmed.2026.108852_bib14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22906","article-title":"Association of preexisting interstitial lung abnormalities with immune checkpoint inhibitor-induced interstitial lung disease among patients with nonlung cancers","volume":"3","author":"Shimoji","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.rmed.2026.108852_bib15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/1759-7714.14718","article-title":"Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer","volume":"14","author":"Murata","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.rmed.2026.108852_bib16","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cllc.2023.08.014","article-title":"Impact of baseline interstitial lung abnormalities on pneumonitis risk in patients receiving immune checkpoint inhibitors for non-small-cell lung cancer","volume":"24","author":"Petranovic","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.rmed.2026.108852_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00262-024-03792-5","article-title":"Outcome of immune checkpoint inhibitor treatment in non-small cell lung cancer patients with interstitial lung abnormalities: clinical utility of subcategorizing interstitial lung abnormalities","volume":"73","author":"Kikuchi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.rmed.2026.108852_bib18","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1093\/oncolo\/oyad187","article-title":"Pre-existing interstitial lung abnormalities and immune checkpoint inhibitor-related pneumonitis in solid tumors: a retrospective analysis","volume":"29","author":"Horiuchi","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.rmed.2026.108852_bib19","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.6004\/jnccn.2023.7059","article-title":"Association between pretreatment chest imaging and immune checkpoint inhibitor pneumonitis among patients with lung cancer","volume":"21","author":"Wong","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.rmed.2026.108852_bib20","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.rmed.2026.108852_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1164\/rccm.202302-0271OC","article-title":"Risk factors, and outcomes of adult interstitial lung abnormalities: a systematic review and meta-analysis","volume":"208","author":"Grant-Orser","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2026.108852_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108458","article-title":"Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: a meta-analysis","volume":"205","author":"Yang","year":"2025","journal-title":"Lung Cancer"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611126002209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:03:42Z","timestamp":1784934222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611126002209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":22,"alternative-id":["S0954611126002209"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108852","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2026.108852","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108852"}}